Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 15/20 | 0.77 |
| ▸ | MEN1 | O00255 | 14/20 | 0.77 |
| ▸ | CTDSP1 | Q9GZU7 | 5/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.77 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.77 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.77 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 7/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.66 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | DDX3X | O00571 | 1/20 | 0.62 |
| ▸ | PTPN12 | Q05209 | 3/20 | 0.61 |
| ▸ | PTPN22 | Q9Y2R2 | 3/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008588 | 0.89 | KMT2A (0.76) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008621 | 0.89 | KMT2A (0.75) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008722 | 0.88 | PTPN12 (0.77) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008721 | 0.87 | KMT2A (0.73) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008607 | 0.87 | KMT2A (0.75) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008595 | 0.87 | KMT2A (1.00) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008594 | 0.86 | KMT2A (1.00) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008597 | 0.86 | PTPN12 (0.79) | KMT2AMEN1CTDSP1TDP1CACNA1B | |
| SCHEMBL13446884 | 0.84 | RAB9A (0.67) | KMT2AMEN1CTDSP1TDP1SAE1 | |
| SCHEMBL12008753 | 0.84 | KMT2A (1.00) | KMT2AMEN1CTDSP1TDP1SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252823-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227624-A1 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885CTDSP1 2910/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885CTDSP1 2910/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | KMT2A 4591/4885MEN1 4655/4885CTDSP1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.